Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Prolia (denosumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Amgen, BeiGene, Daiichi Sankyo, GSK

Drug class:

RANK ligand inhibitor

Related drugs:

‹

denosumab-bddz (1)

LY01011 (denosumab biosimilar) (0)

denosumab-bddz (1)

LY01011 (denosumab biosimilar) (0)

›

No biomarker	Giant Cell Tumor of Bone	No biomarker	Giant Cell Tumor of Bone	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
No biomarker	Breast Cancer	No biomarker	Breast Cancer	denosumab Resistant: A2 - Guideline denosumab Resistant : A2	denosumab Resistant: A2 - Guideline denosumab Resistant : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	denosumab Sensitive: B - Late Trials denosumab Sensitive : B	denosumab Sensitive: B - Late Trials denosumab Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	denosumab Sensitive: B - Late Trials denosumab Sensitive : B	denosumab Sensitive: B - Late Trials denosumab Sensitive : B
KRAS exon 12 mutation	Non Small Cell Lung Cancer	KRAS exon 12 mutation	Non Small Cell Lung Cancer	denosumab Sensitive: C3 – Early Trials denosumab Sensitive : C3	denosumab Sensitive: C3 – Early Trials denosumab Sensitive : C3
HR positive + TNFRSF11A overexpression	HER2 Negative Breast Cancer	HR positive + TNFRSF11A overexpression	HER2 Negative Breast Cancer	denosumab Sensitive: C3 – Early Trials denosumab Sensitive : C3	denosumab Sensitive: C3 – Early Trials denosumab Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	denosumab Sensitive: C3 – Early Trials denosumab Sensitive : C3	denosumab Sensitive: C3 – Early Trials denosumab Sensitive : C3
H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone	H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone	denosumab Resistant: C4 – Case Studies denosumab Resistant : C4	denosumab Resistant: C4 – Case Studies denosumab Resistant : C4